Novartis' IL-17 inhibitor approved in U.S. and EU

Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) this week became the first IL-17 inhibitor to be approved in the U.S. and the EU. On Wednesday, FDA

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE